Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody drug conjugates (ADCs) within an existing deal with China’s Duality Biologics. This move follows Adcendo’s initial licensing agreement in January 2023, which granted access to Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker-payload platform for its lead uPARAP-ADC program targeting mesenchymal cancers.
Nomination of New ADC Targets and Platform Access
Following a thorough evaluation period, Adcendo has now nominated ADCs against two novel targets and licensed access to Duality’s platform. This strategic expansion builds on the success of the initial partnership and signifies Adcendo’s commitment to advancing its pipeline in the development of innovative cancer therapies.
Financial Details and Terms
The previous January 2023 deal included an undisclosed upfront fee, milestone payments, and tiered royalties. No new financial specifics or terms have been disclosed for this expanded partnership, maintaining the confidentiality of the commercial arrangements between Adcendo ApS and Duality Biologics.-Fineline Info & Tech
